Johnson & Johnson has added another piece to the data behind its effort to move Tecvayli into earlier-line therapy for multiple myeloma, including the first relapse setting. In the MajesTEC-9 trial, ...
As PCMag's resident data journalist, I practically live in Microsoft Excel. I've learned that it's capable of far more than I ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results